Liver Institute Northwest

Recent papers from Liver Institute Northwest

1. Elafibranor improves biochemical response and favorably modifies GLOBE and UK-PBC prognostic scores in primary biliary cholangitis: analyses from the phase III ELATIVE® trialBMC Gastroenterology · 2026
2. Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trialHepatology · 2026
3. A phase 2b/3 trial of saroglitazar in primary biliary cholangitisHepatology · 2026
4. Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)Hepatology · 2026
5. PSC ‐ DM : A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing CholangitisLiver International · 2026
6. Delphi expert consensus on phlebotomy limitations and treatment challenges in HFE -related hemochromatosisClinical Hematology International · 2026
7. Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United StatesJournal of Comparative Effectiveness Research · 2026
8. Burden of fatigue or pruritus in patients with primary biliary cholangitis: a United States matched case-control study.2026
9. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trialJournal of Hepatology · 2026
10. Transarterial chemoembolization combined with sorafenib versus monotherapy for unresectable hepatocellular carcinoma: An umbrella review of meta-analysesCanadian Liver Journal · 2026
11. Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety ExtensionAlimentary Pharmacology & Therapeutics · 2026
12. The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver diseaseNature Communications · 2026
13. Development of a Patient Journey Map for Metabolic Dysfunction–Associated Steatohepatitis: A Comprehensive Assessment of the Patient Journey in North AmericaJournal of Patient Experience · 2026
14. Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trialHepatology · 2026
15. Evolving Concepts of Treatment Targets for PBC: A Global PerspectiveThe American Journal of Gastroenterology · 2026
16. Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVELiver International · 2026
17. Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE TrialAlimentary Pharmacology & Therapeutics · 2026
18. Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic PotentialDrug Design Development and Therapy · 2026
19. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet · 2026
20. Shaping the future of clinical trials through strategic foresightClinical Trials · 2026